Microbiotix, a recipient of CARB-X awards for two of its innovative antibacterial programs, is a Worcester, MA-based clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments that target serious infectious diseases. Microbiotix’s lead product candidate, MBX-400 (filociclovir), a novel, potent nucleoside analog inhibitor, is in preclinical development as a first-in-class antiviral for adenoviral conjunctivitis, the most common cause of infectious conjunctivitis worldwide. As no current therapy exists to treat patients, palliative care is often utilized, leaving severe cases to potential long term sequelae and loss of sight. MBX-400 is a potent, broad-spectrum inhibitor of adenoviruses, with excellent tolerability and best-in-class in vivo efficacy in an ocular infection model. MBX-400 has also successfully completed Phase 1 clinical trials in our CMV/transplantation program.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):